Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Juan Taveras

Cardiovascular Disease El Paso, TX Medical Doctor

NPI 1932109683 CMS profile 268604

4301 N Mesa St, Ste 101, El Paso, TX 79902

Open in the dashboard

General payments

$91,000

797 records reported · program years 2019–2025

Research payments

$6,488

Paid to them · 11 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,375 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Juan Taveras of El Paso, TX is reported in the CMS Open Payments database as having received $91,000 across 797 general payments and $6,488 in research payments paid to them. Separately, studies naming them as principal investigator received $3,375 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,042 124
2024 General $7,198 136
2023 General $8,435 148
2022 General $21,776 138
2021 General $21,897 92
2020 General $11,676 52
2019 General $16,975 107
2019 Research $6,488 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Juan Taveras
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Juan Taveras were reported at $3,042. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Juan Taveras Cardiovascular Disease median Middle half National median
2019 $16,975 $450 $127–$1,392 $163
2020 $11,676 $242 $77–$751 $114
2021 $21,897 $335 $101–$1,037 $132
2022 $21,776 $395 $121–$1,211 $149
2023 $8,435 $443 $136–$1,283 $160
2024 $7,198 $450 $136–$1,323 $164
2025 $3,042 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $61,724 90 payments
  2. Abbott Laboratories $7,232 81 payments
  3. Medtronic, Inc. $6,576 131 payments
  4. AstraZeneca Pharmaceuticals LP $5,358 18 payments
  5. Boston Scientific Corporation $1,456 69 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $1,143 59 payments
  7. Novartis Pharmaceuticals Corporation $1,086 81 payments
  8. E.R. Squibb & Sons, L.L.C. $718 56 payments
  9. Amgen Inc. $608 37 payments
  10. Merck Sharp & Dohme Corporation $499 25 payments
  11. Other $4,600 150 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $64,344 31 payments
  2. Food and Beverage $21,957 748 payments
  3. Consulting Fee $2,925 2 payments
  4. Travel and Lodging $1,392 10 payments
  5. Education $307 5 payments
  6. Debt forgiveness $74 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $61,716 89 payments
  2. FARXIGA $5,266 12 payments
  3. Micra $3,427 52 payments
  4. Accent Pacemaker $2,799 2 payments
  5. COBALT DR MRI SURESCAN $677 19 payments
  6. JARDIANCE Diabetes $619 25 payments
  7. VERQUVO $596 29 payments
  8. Quadra Assura CRT Defibrillator $576 8 payments
  9. ENTRESTO $525 39 payments
  10. JARDIANCE Diabetes $525 34 payments
  11. Other $13,716 524 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Abbott Laboratories $6,488 11 payments

Prescribing to Medicare patients

Part D · data year 2024 · 57 drugs

Part D claims

5,420

Median for Cardiology: 2,533

Drug cost

$1,080,427

Median for Cardiology: $485,213

Branded share of claims

24.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 294 $395,677
Eliquis Apixaban Brand 216 $275,662
Entresto Sacubitril/Valsartan Brand 133 $169,031
Repatha Syringe Evolocumab Brand 62 $55,571
Farxiga Dapagliflozin Propanediol Brand 45 $54,777
Jardiance Empagliflozin Brand 32 $50,209
Brilinta Ticagrelor Brand 16 $15,500
Ranolazine Er Ranolazine Brand 109 $13,339
Metoprolol Succinate Generic 624 $7,012
Isosorbide Dinitrate Generic 57 $2,599

The 10 drugs with the highest cost, of 57 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$73,612

Medicare's payments for the services billed

Medicare patients

540

Average age 75

Services billed

1,455

300 women, 240 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 56%
Chronic kidney disease 53%
Arthritis 48%
Ischemic heart disease 41%
Heart failure 39%
Atrial fibrillation 30%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $4,232
$4,232 294 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $387
$387 32 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $111
$111 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $98
$98 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $86
$86 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

808 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record